---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-22-000169"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T02:47:45.761114+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics Q3 revenue $129M (+6%); net loss widens to $37M, adjusted EBITDA -$12M

## Summary
- Revenue $129M (+6% YoY); Clinical Services $106M (+4%), Pharma Services $23M (+18%).
- Test volume -1% YoY; revenue per test +5% to $392.
- Net loss $37M (vs $20M loss in Q3 2021); prior year included $18M gain on Inivata investment.
- Adjusted EBITDA -$12M (vs -$3M); Adjusted Net Loss -$18M (vs -$10M).
- Cash and marketable securities $444M at quarter end.

## SEC filing metadata
- accession: 0001077183-22-000169
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000169/0001077183-22-000169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000169/neo-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-22-000169
- JSON: https://secwatch.observer/filing/0001077183-22-000169.json
- Plain text: https://secwatch.observer/filing/0001077183-22-000169.txt

## Key facts
- Earnings Releases
  NEOGENOMICS INC reported the third quarter of 2022 results: revenue $129 million, net income $37 million.
  - Period: the third quarter of 2022
  - Revenue: $129 million
  - Net income: $37 million
  - Result: reported results
  source text: Third-Quarter Results Consolidated revenue for the third quarter of 2022 was $129 million, an increase of 6% over the same period in 2021. Clinical Services revenue of $106 million was an increase year-over-year of 4%. Clinical test volume (1) decreased by 1% year-over-year. Average revenue per clinical test (“revenue per test”) increased by 5% to $392. Pharma Services revenue increased by 18% to $23 million compared to the third quarter of 2021. Consolidated gross profit for the third quarter of 2022 was $48.9 million, an increase of 4% compared to the third quarter of 2021. This increase was primarily due to an increase in revenue partially offset by higher payroll and payroll-related costs. Consolidated gross profit margin, including amortization of acquired Inivata developed technology intangible assets, was 38.0%. Adjusted Gross Profit Margin (2) , excluding amortization of acquired Inivata developed technology intangible assets, was 41.7%. Operating expenses for the third quarter
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000169/0001077183-22-000169-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.